Cargando…
A Retrospective Study of Dexamethasone, Remdesivir, and Baricitinib in Severe COVID-19
PURPOSE: RECOVERY, ACTT-1, and ACTT-2 trials have demonstrated that utilization of dexamethasone, remdesivir, or a combination of remdesivir with baricitinib leads to mortality benefit and faster time to recovery, respectively. However, no studies have investigated the benefit of triple therapy of d...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9279094/ https://www.ncbi.nlm.nih.gov/pubmed/35845297 http://dx.doi.org/10.1155/2022/9209618 |
_version_ | 1784746318730625024 |
---|---|
author | Ngo, Dallis Q. Hamid, Kewan Rana, Haris Cardinale, Maria Frenia, Douglas Ghani, Nabil Redel, Henry |
author_facet | Ngo, Dallis Q. Hamid, Kewan Rana, Haris Cardinale, Maria Frenia, Douglas Ghani, Nabil Redel, Henry |
author_sort | Ngo, Dallis Q. |
collection | PubMed |
description | PURPOSE: RECOVERY, ACTT-1, and ACTT-2 trials have demonstrated that utilization of dexamethasone, remdesivir, or a combination of remdesivir with baricitinib leads to mortality benefit and faster time to recovery, respectively. However, no studies have investigated the benefit of triple therapy of dexamethasone, remdesivir, and baricitinib. We investigate the benefits of triple therapy compared to dual therapy of dexamethasone with remdesivir in patients with severe COVID-19 on HFNC. MATERIALS AND METHODS: A retrospective data analysis was performed on patients with severe COVID-19 requiring HFNC and evaluated for hospital discharge status, requirement of mechanical ventilation, length of stay, and days on HFNC. RESULTS: Among 191 patients with severe COVID-19, 81 patients received dexamethasone, remdesivir, and baricitinib. Patients receiving triple therapy had a significant survival benefit (HR 0.52; P=0.042). Treatment with triple therapy vs. dual therapy also trended towards less requirement of mechanical ventilation (OR 0.66; P=0.26). There was no significant change in length of stay (mean 13.74 vs. 13.31; P=0.74) or days on HFNC (mean 8.95 vs. 7.28 days, P=0.16). CONCLUSIONS: The use of dexamethasone, remdesivir, and baricitinib in patients with severe COVID-19 requiring HFNC was associated with a significant survival benefit in comparison to dual therapy of dexamethasone with remdesivir. |
format | Online Article Text |
id | pubmed-9279094 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-92790942022-07-14 A Retrospective Study of Dexamethasone, Remdesivir, and Baricitinib in Severe COVID-19 Ngo, Dallis Q. Hamid, Kewan Rana, Haris Cardinale, Maria Frenia, Douglas Ghani, Nabil Redel, Henry Can J Infect Dis Med Microbiol Research Article PURPOSE: RECOVERY, ACTT-1, and ACTT-2 trials have demonstrated that utilization of dexamethasone, remdesivir, or a combination of remdesivir with baricitinib leads to mortality benefit and faster time to recovery, respectively. However, no studies have investigated the benefit of triple therapy of dexamethasone, remdesivir, and baricitinib. We investigate the benefits of triple therapy compared to dual therapy of dexamethasone with remdesivir in patients with severe COVID-19 on HFNC. MATERIALS AND METHODS: A retrospective data analysis was performed on patients with severe COVID-19 requiring HFNC and evaluated for hospital discharge status, requirement of mechanical ventilation, length of stay, and days on HFNC. RESULTS: Among 191 patients with severe COVID-19, 81 patients received dexamethasone, remdesivir, and baricitinib. Patients receiving triple therapy had a significant survival benefit (HR 0.52; P=0.042). Treatment with triple therapy vs. dual therapy also trended towards less requirement of mechanical ventilation (OR 0.66; P=0.26). There was no significant change in length of stay (mean 13.74 vs. 13.31; P=0.74) or days on HFNC (mean 8.95 vs. 7.28 days, P=0.16). CONCLUSIONS: The use of dexamethasone, remdesivir, and baricitinib in patients with severe COVID-19 requiring HFNC was associated with a significant survival benefit in comparison to dual therapy of dexamethasone with remdesivir. Hindawi 2022-07-06 /pmc/articles/PMC9279094/ /pubmed/35845297 http://dx.doi.org/10.1155/2022/9209618 Text en Copyright © 2022 Dallis Q. Ngo et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Ngo, Dallis Q. Hamid, Kewan Rana, Haris Cardinale, Maria Frenia, Douglas Ghani, Nabil Redel, Henry A Retrospective Study of Dexamethasone, Remdesivir, and Baricitinib in Severe COVID-19 |
title | A Retrospective Study of Dexamethasone, Remdesivir, and Baricitinib in Severe COVID-19 |
title_full | A Retrospective Study of Dexamethasone, Remdesivir, and Baricitinib in Severe COVID-19 |
title_fullStr | A Retrospective Study of Dexamethasone, Remdesivir, and Baricitinib in Severe COVID-19 |
title_full_unstemmed | A Retrospective Study of Dexamethasone, Remdesivir, and Baricitinib in Severe COVID-19 |
title_short | A Retrospective Study of Dexamethasone, Remdesivir, and Baricitinib in Severe COVID-19 |
title_sort | retrospective study of dexamethasone, remdesivir, and baricitinib in severe covid-19 |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9279094/ https://www.ncbi.nlm.nih.gov/pubmed/35845297 http://dx.doi.org/10.1155/2022/9209618 |
work_keys_str_mv | AT ngodallisq aretrospectivestudyofdexamethasoneremdesivirandbaricitinibinseverecovid19 AT hamidkewan aretrospectivestudyofdexamethasoneremdesivirandbaricitinibinseverecovid19 AT ranaharis aretrospectivestudyofdexamethasoneremdesivirandbaricitinibinseverecovid19 AT cardinalemaria aretrospectivestudyofdexamethasoneremdesivirandbaricitinibinseverecovid19 AT freniadouglas aretrospectivestudyofdexamethasoneremdesivirandbaricitinibinseverecovid19 AT ghaninabil aretrospectivestudyofdexamethasoneremdesivirandbaricitinibinseverecovid19 AT redelhenry aretrospectivestudyofdexamethasoneremdesivirandbaricitinibinseverecovid19 AT ngodallisq retrospectivestudyofdexamethasoneremdesivirandbaricitinibinseverecovid19 AT hamidkewan retrospectivestudyofdexamethasoneremdesivirandbaricitinibinseverecovid19 AT ranaharis retrospectivestudyofdexamethasoneremdesivirandbaricitinibinseverecovid19 AT cardinalemaria retrospectivestudyofdexamethasoneremdesivirandbaricitinibinseverecovid19 AT freniadouglas retrospectivestudyofdexamethasoneremdesivirandbaricitinibinseverecovid19 AT ghaninabil retrospectivestudyofdexamethasoneremdesivirandbaricitinibinseverecovid19 AT redelhenry retrospectivestudyofdexamethasoneremdesivirandbaricitinibinseverecovid19 |